PORTOLA VALLEY, Calif., May 19 /PRNewswire/ -- Spectros announced today that its T-Stat Tissue Oximeter was featured in two presentations at the Pediatric Academic Societies' (PAS) annual conference held in Baltimore, Maryland, May 2-5, 2009. The studies focused on clinical applications of the Spectros T-Stat monitor in the neonatal intensive care unit (NICU).
The first abstract was titled, "Visible Light Spectroscopy (VLS) for Detecting Alterations in Tissue Oxygenation with PRBC Transfusion in Very Low Birth Weight (VLBW) Neonates." The authors noted, "VLS is an easy to use and noninvasive method of assessment of tissue saturation in VLBW neonates with various severity of illness."
The second poster was titled, "Noninvasive Measurements of Plasma Bilirubin Levels Using Real-Time Visible Light Spectroscopy." The authors concluded visible light spectroscopy can be used as a method to measure real-time plasma bilirubin levels noninvasively. This compliments prior studies showing T-Stat can measure tissue or plasma met-hemoglobin and carboxy-hemoglobin.
"The utilization and acceptance of T-Stat has grown tremendously over the past 16 months as clinicians have increasingly recognized the need to monitor tissue perfusion in a reliable, reproducible, and quantitative way," commented Michael Fierro, Director of Clinical Studies. "We have additional studies in progress and will continue to demonstrate the efficacy of the T-Stat in reducing hospitalization costs and improving outcome in this high-risk population."
Spectros markets advanced molecular sensing and imaging devices that shed light on ischemia and cancer. The company's lead product, the T-Stat Tissue Oximeter, was the first medical device FDA-approved as sensitive to ischemia, an insufficient blood flow to tissue. T-Stat is the only commercially-available tissue oximeter that utilizes state-of-the-art visible light spectroscopy (VLS) technology. In clinical use, T-Stat is a real-time, absolute, noninvasive, and continuous tissue monitor that analyzes 260 wavelengths of light, far more than the 2-4 wavelengths used in other monitors for superior accuracy.
Spectros is also developing molecular diagnostic tools for breast and prostate cancer currently in phase I/II clinical trials supported by the National Cancer Institute. Spectros is a venture-supported private concern and markets its products in the U.S. and internationally.
(Note: Forward-looking statements are intended as a guide only, and do not constitute an offer for investment nor a guarantee of future events or returns. Certain Spectros applications described above have not been reviewed and approved by the FDA, and are for investigational use only. T-Stat is a registered trademark of the Spectros Corporation.)
Copyright©2009 PR Newswire.
All rights reserved